BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 10023685)

  • 1. Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.
    Arriola EL; Lopez AR; Chresta CM
    Oncogene; 1999 Jan; 18(4):1081-91. PubMed ID: 10023685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.
    Richie JP
    J Urol; 2005 Sep; 174(3):931-2. PubMed ID: 16093994
    [No Abstract]   [Full Text] [Related]  

  • 3. Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells.
    Morgan SE; Kim R; Wang PC; Bhat UG; Kusumoto H; Lu T; Beck WT
    Oncogene; 2000 Oct; 19(43):5010-9. PubMed ID: 11042688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
    Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH
    J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mdm2 inhibition of p53 induces E2F1 transactivation via p21.
    Wunderlich M; Berberich SJ
    Oncogene; 2002 Jun; 21(28):4414-21. PubMed ID: 12080472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of proteins in p53 (p14ARF-mdm2-p53-p21WAF/CIP1) pathway and their significance in exocrine pancreatic carcinoma].
    Yu GZ; Zhu MH; Ni CR; Li FM; Zheng JM; Gong ZJ
    Zhonghua Bing Li Xue Za Zhi; 2004 Apr; 33(2):130-4. PubMed ID: 15132849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential regulation of the p21/WAF-1 and mdm2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene.
    Wu L; Levine AJ
    Mol Med; 1997 Jul; 3(7):441-51. PubMed ID: 9260156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDM2 mediated nuclear exclusion of p53 attenuates etoposide-induced apoptosis in neuroblastoma cells.
    Rodriguez-Lopez AM; Xenaki D; Eden TO; Hickman JA; Chresta CM
    Mol Pharmacol; 2001 Jan; 59(1):135-43. PubMed ID: 11125034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additive effect of adenovirus-mediated E2F-1 gene transfer and topoisomerase II inhibitors on apoptosis in human osteosarcoma cells.
    Yang HL; Dong YB; Elliott MJ; Wong SL; McMasters KM
    Cancer Gene Ther; 2001 Apr; 8(4):241-51. PubMed ID: 11393276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of apoptosis in human retinoblastoma cells by topoisomerase inhibitors.
    Giuliano M; Lauricella M; Vassallo E; Carabillò M; Vento R; Tesoriere G
    Invest Ophthalmol Vis Sci; 1998 Jul; 39(8):1300-11. PubMed ID: 9660477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma.
    Jahnson S; Karlsson MG
    Cancer; 2000 Aug; 89(3):619-29. PubMed ID: 10931462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
    Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
    Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
    Wang H; Yu D; Agrawal S; Zhang R
    Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes.
    Pfister C; Larue H; Moore L; Lacombe L; Veilleux C; Tetu B; Meyer F; Fradet Y
    Int J Cancer; 2000 Jan; 89(1):100-4. PubMed ID: 10719738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein.
    Landers JE; Cassel SL; George DL
    Cancer Res; 1997 Aug; 57(16):3562-8. PubMed ID: 9270029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity.
    Piovesan B; Pennell N; Berinstein NL
    Oncogene; 1998 Nov; 17(18):2339-50. PubMed ID: 9811465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 and p21WAF1/CIP1, wild-type p53-induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin's disease.
    Sánchez-Beato M; Piris MA; Martínez-Montero JC; García JF; Villuendas R; García FJ; Orradre JL; Martínez P
    J Pathol; 1996 Sep; 180(1):58-64. PubMed ID: 8943816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of p53 target gene expression by cisplatin-induced extracellular signal-regulated kinase.
    DeHaan RD; Yazlovitskaya EM; Persons DL
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):383-8. PubMed ID: 11761456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An abnormality in the p53 pathway following gamma-irradiation in many wild-type p53 human melanoma lines.
    Bae I; Smith ML; Sheikh MS; Zhan Q; Scudiero DA; Friend SH; O'Connor PM; Fornace AJ
    Cancer Res; 1996 Feb; 56(4):840-7. PubMed ID: 8631022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations.
    Villuendas R; Pezzella F; Gatter K; Algara P; Sánchez-Beato M; Martínez P; Martínez JC; Muñoz K; García P; Sánchez L; Kocialkowsky S; Campo E; Orradre JL; Piris MA
    J Pathol; 1997 Jan; 181(1):51-61. PubMed ID: 9072003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.